Compile Data Set for Download or QSAR
Report error Found 3962 Enz. Inhib. hit(s) with Target = 'Serine/threonine-protein kinase Chk1'
TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402004(US10010547, Example 112 | 5-[[5-[4-[(1-isopropyl-4...)
Affinity DataIC50: 0.00400nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402004(US10010547, Example 112 | 5-[[5-[4-[(1-isopropyl-4...)
Affinity DataIC50: 0.00400nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402003(US10010547, Example 111 | 5-[[5-[4-[(1-ethyl-4-pip...)
Affinity DataIC50: 0.00500nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402003(US10010547, Example 111 | 5-[[5-[4-[(1-ethyl-4-pip...)
Affinity DataIC50: 0.00500nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402002(US10010547, Example 110 | 5-[[5-[2-methoxy-4-[(1-m...)
Affinity DataIC50: 0.00700nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402002(US10010547, Example 110 | 5-[[5-[2-methoxy-4-[(1-m...)
Affinity DataIC50: 0.00700nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402035(US10010547, Example 145 | 5-[[5-[4-[(1-ethyl-4-pip...)
Affinity DataIC50: 0.00800nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402035(US10010547, Example 145 | 5-[[5-[4-[(1-ethyl-4-pip...)
Affinity DataIC50: 0.00800nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402036(US10010547, Example 146 | 5-[[5-[4-[(isobutylamino...)
Affinity DataIC50: 0.0120nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402036(US10010547, Example 146 | 5-[[5-[4-[(isobutylamino...)
Affinity DataIC50: 0.0120nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM401974(US10010547, Example 82 | 5-[[5-[2-methoxy-4-[(3R)-...)
Affinity DataIC50: 0.0160nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM401974(US10010547, Example 82 | 5-[[5-[2-methoxy-4-[(3R)-...)
Affinity DataIC50: 0.0160nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM401984(US10010547, Example 92 | 5-[[5-[4-[(3R)-3,4-dimeth...)
Affinity DataIC50: 0.0160nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM401985(US10010547, Example 93 | 5-[[5-[4-[(3R)-4-ethyl-3-...)
Affinity DataIC50: 0.0160nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM401985(US10010547, Example 93 | 5-[[5-[4-[(3R)-4-ethyl-3-...)
Affinity DataIC50: 0.0160nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM401984(US10010547, Example 92 | 5-[[5-[4-[(3R)-3,4-dimeth...)
Affinity DataIC50: 0.0160nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402031(US10010547, Example 141 | 5-[[5-[4-[[(3R)-1-isopro...)
Affinity DataIC50: 0.0190nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402031(US10010547, Example 141 | 5-[[5-[4-[[(3R)-1-isopro...)
Affinity DataIC50: 0.0190nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402030(US10010547, Example 140 | 5-[[5-[4-[[(3R)-1-ethylp...)
Affinity DataIC50: 0.0210nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402033(US10010547, Example 143 | 5-[[5-[4-[(1-ethyl-4-pip...)
Affinity DataIC50: 0.0210nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402033(US10010547, Example 143 | 5-[[5-[4-[(1-ethyl-4-pip...)
Affinity DataIC50: 0.0210nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402030(US10010547, Example 140 | 5-[[5-[4-[[(3R)-1-ethylp...)
Affinity DataIC50: 0.0210nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402010(US10010547, Example 118 | 5-[[5-[2-methoxy-4-[(2R)...)
Affinity DataIC50: 0.0220nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM401957(US10010547, Example 65 | 5-[[5-[2-methoxy-4-(1-met...)
Affinity DataIC50: 0.0220nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM401957(US10010547, Example 65 | 5-[[5-[2-methoxy-4-(1-met...)
Affinity DataIC50: 0.0220nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402010(US10010547, Example 118 | 5-[[5-[2-methoxy-4-[(2R)...)
Affinity DataIC50: 0.0220nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402018(US10010547, Example 128 | 5-[[5-[4-[[(2S)-1-ethylp...)
Affinity DataIC50: 0.0230nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402018(US10010547, Example 128 | 5-[[5-[4-[[(2S)-1-ethylp...)
Affinity DataIC50: 0.0230nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402020(US10010547, Example 130 | 5-[[5-[4-[(cyclopropylme...)
Affinity DataIC50: 0.0250nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402020(US10010547, Example 130 | 5-[[5-[4-[(cyclopropylme...)
Affinity DataIC50: 0.0250nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM401914(US10010547, Example 22 | 5-[[5-[2-methoxy-4-(4-met...)
Affinity DataIC50: 0.0260nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM401906(US10010547, Example 14 | 5-[[5-[2-methoxy-4-[(tetr...)
Affinity DataIC50: 0.0260nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402034(US10010547, Example 144 | 5-[[5-[4-[(1-isopropyl-4...)
Affinity DataIC50: 0.0260nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM401906(US10010547, Example 14 | 5-[[5-[2-methoxy-4-[(tetr...)
Affinity DataIC50: 0.0260nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402034(US10010547, Example 144 | 5-[[5-[4-[(1-isopropyl-4...)
Affinity DataIC50: 0.0260nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM401914(US10010547, Example 22 | 5-[[5-[2-methoxy-4-(4-met...)
Affinity DataIC50: 0.0260nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402009(US10010547, Example 117 | 5-[[5-[2-methoxy-4-[(2R)...)
Affinity DataIC50: 0.0270nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402009(US10010547, Example 117 | 5-[[5-[2-methoxy-4-[(2R)...)
Affinity DataIC50: 0.0270nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402029(US10010547, Example 139 | 5-[[5-[4-[[(3S)-1-isopro...)
Affinity DataIC50: 0.0270nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402029(US10010547, Example 139 | 5-[[5-[4-[[(3S)-1-isopro...)
Affinity DataIC50: 0.0270nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM50379642(CHEMBL2011352)
Affinity DataIC50: 0.0300nMAssay Description:Competitive inhibition of Chk1 in presence of higher ATP levelsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2013
Entry Details Article
PubMed
TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM120931(US8716287, 64)
Affinity DataIC50: 0.0300nMpH: 7.5Assay Description:The compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set out below. Reaction Buffer: Base R...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2014
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM50379643(CHEMBL2011353)
Affinity DataIC50: 0.0300nMAssay Description:Competitive inhibition of Chk1 in presence of higher ATP levelsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2013
Entry Details Article
PubMed
TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM50379642(CHEMBL2011352)
Affinity DataIC50: 0.0300nMAssay Description:Inhibition of CHK1 by time resolved fluorescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2013
Entry Details Article
PubMed
TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM50379643(CHEMBL2011353)
Affinity DataIC50: 0.0300nMAssay Description:Inhibition of CHK1 by time resolved fluorescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/7/2013
Entry Details Article
PubMed
TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402038(US10010547, Example 148 | 5-[[5-[4-[(1-isopropyl-4...)
Affinity DataIC50: 0.0310nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402038(US10010547, Example 148 | 5-[[5-[4-[(1-isopropyl-4...)
Affinity DataIC50: 0.0310nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM401904(US10010547, Example 12 | 5-[5-(4-{[(1-cyclopropane...)
Affinity DataIC50: 0.0340nMAssay Description:Chk-1 Kinase Inhibiting ActivityThe compounds of the invention were tested for activity against Chk-1 kinase using the materials and protocols set ou...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/26/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM401904(US10010547, Example 12 | 5-[5-(4-{[(1-cyclopropane...)
Affinity DataIC50: 0.0340nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

TargetSerine/threonine-protein kinase Chk1(Human)
Cascadian Therapeutics

US Patent
LigandPNGBDBM402028(US10010547, Example 138 | 5-[[5-[4-[[(3S)-1-ethylp...)
Affinity DataIC50: 0.0410nMAssay Description:Base Reaction buffer: 20 mM Hepes (pH 7.5), 10 mM MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO Required cofactors...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/20/2021
Entry Details
US Patent

Displayed 1 to 50 (of 3962 total ) | Next | Last >>
Jump to: